vs
Nurix Therapeutics, Inc.（NRIX）与RIVERVIEW BANCORP INC（RVSB）财务数据对比。点击上方公司名可切换其他公司
RIVERVIEW BANCORP INC的季度营收约是Nurix Therapeutics, Inc.的1.0倍（$14.0M vs $13.6M），RIVERVIEW BANCORP INC净利率更高（9.8% vs -576.1%，领先585.9%），RIVERVIEW BANCORP INC同比增速更快（10.4% vs 2.2%），RIVERVIEW BANCORP INC自由现金流更多（$-736.0K vs $-73.0M），过去两年RIVERVIEW BANCORP INC的营收复合增速更高（24.6% vs -9.5%）
Nurix Therapeutics是一家临床阶段生物制药企业，专注于发现、开发及商业化针对癌症、免疫疾病等存在重大未满足医疗需求的新型靶向蛋白降解疗法，依托专有的E3泛素连接酶调节技术推进管线研发，与全球多家制药企业达成合作。
Riverview Bancorp Inc.是一家总部位于美国的银行控股公司，主营个人与商业银行业务，服务覆盖太平洋西北地区，提供存款、消费贷款、住房抵押贷款、商业信贷及小企业金融等产品，服务零售客户与本地企业群体。
NRIX vs RVSB — 直观对比
营收规模更大
RVSB
是对方的1.0倍
$13.6M
营收增速更快
RVSB
高出8.2%
2.2%
净利率更高
RVSB
高出585.9%
-576.1%
自由现金流更多
RVSB
多$72.2M
$-73.0M
两年增速更快
RVSB
近两年复合增速
-9.5%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $13.6M | $14.0M |
| 净利润 | $-78.2M | $1.4M |
| 毛利率 | — | — |
| 营业利润率 | -612.0% | 12.4% |
| 净利率 | -576.1% | 9.8% |
| 营收同比 | 2.2% | 10.4% |
| 净利润同比 | -33.6% | 11.8% |
| 每股收益（稀释后） | $-0.83 | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NRIXRVSB
| Q4 25 | $13.6M | $14.0M | ||
| Q3 25 | $7.9M | $13.6M | ||
| Q2 25 | $44.1M | $13.3M | ||
| Q1 25 | $18.5M | $12.9M | ||
| Q4 24 | $13.3M | $12.7M | ||
| Q3 24 | $12.6M | $12.8M | ||
| Q2 24 | $12.1M | $12.2M | ||
| Q1 24 | $16.6M | $9.0M |
净利润NRIXRVSB
| Q4 25 | $-78.2M | $1.4M | ||
| Q3 25 | $-86.4M | $1.1M | ||
| Q2 25 | $-43.5M | $1.2M | ||
| Q1 25 | $-56.4M | $1.1M | ||
| Q4 24 | $-58.5M | $1.2M | ||
| Q3 24 | $-49.0M | $1.6M | ||
| Q2 24 | $-44.5M | $966.0K | ||
| Q1 24 | $-41.5M | $-3.0M |
营业利润率NRIXRVSB
| Q4 25 | -612.0% | 12.4% | ||
| Q3 25 | -1157.7% | 10.2% | ||
| Q2 25 | -109.7% | 11.7% | ||
| Q1 25 | -340.7% | 11.3% | ||
| Q4 24 | -486.7% | 12.4% | ||
| Q3 24 | -433.8% | 15.5% | ||
| Q2 24 | -401.4% | 10.0% | ||
| Q1 24 | -272.6% | -47.5% |
净利率NRIXRVSB
| Q4 25 | -576.1% | 9.8% | ||
| Q3 25 | -1094.8% | 8.1% | ||
| Q2 25 | -98.7% | 9.2% | ||
| Q1 25 | -305.4% | 8.9% | ||
| Q4 24 | -440.7% | 9.7% | ||
| Q3 24 | -388.9% | 12.2% | ||
| Q2 24 | -368.4% | 7.9% | ||
| Q1 24 | -250.3% | -34.7% |
每股收益（稀释后）NRIXRVSB
| Q4 25 | $-0.83 | $0.07 | ||
| Q3 25 | $-1.03 | $0.05 | ||
| Q2 25 | $-0.52 | $0.06 | ||
| Q1 25 | $-0.67 | $0.05 | ||
| Q4 24 | $-0.74 | $0.06 | ||
| Q3 24 | $-0.67 | $0.07 | ||
| Q2 24 | $-0.71 | $0.05 | ||
| Q1 24 | $-0.76 | $-0.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $247.0M | $28.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $538.7M | $164.2M |
| 总资产 | $688.1M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NRIXRVSB
| Q4 25 | $247.0M | $28.6M | ||
| Q3 25 | $78.4M | $32.8M | ||
| Q2 25 | $84.3M | $34.2M | ||
| Q1 25 | $75.9M | $29.4M | ||
| Q4 24 | $110.0M | $25.3M | ||
| Q3 24 | $99.0M | $31.0M | ||
| Q2 24 | $116.8M | $27.8M | ||
| Q1 24 | $49.8M | $23.6M |
股东权益NRIXRVSB
| Q4 25 | $538.7M | $164.2M | ||
| Q3 25 | $372.3M | $163.5M | ||
| Q2 25 | $447.6M | $162.0M | ||
| Q1 25 | $480.9M | $160.0M | ||
| Q4 24 | $527.0M | $158.3M | ||
| Q3 24 | $376.9M | $160.8M | ||
| Q2 24 | $370.7M | $155.9M | ||
| Q1 24 | $168.7M | $155.6M |
总资产NRIXRVSB
| Q4 25 | $688.1M | $1.5B | ||
| Q3 25 | $522.5M | $1.5B | ||
| Q2 25 | $591.6M | $1.5B | ||
| Q1 25 | $615.0M | $1.5B | ||
| Q4 24 | $669.3M | $1.5B | ||
| Q3 24 | $513.6M | $1.5B | ||
| Q2 24 | $511.0M | $1.5B | ||
| Q1 24 | $312.7M | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-67.8M | $-506.0K |
| 自由现金流经营现金流 - 资本支出 | $-73.0M | $-736.0K |
| 自由现金流率自由现金流/营收 | -537.4% | -5.2% |
| 资本支出强度资本支出/营收 | 37.8% | 1.6% |
| 现金转化率经营现金流/净利润 | — | -0.37× |
| 过去12个月自由现金流最近4个季度 | $-263.5M | $20.4M |
8季度趋势，按日历期对齐
经营现金流NRIXRVSB
| Q4 25 | $-67.8M | $-506.0K | ||
| Q3 25 | $-57.4M | $16.8M | ||
| Q2 25 | $-63.2M | $-697.0K | ||
| Q1 25 | $-61.1M | $8.3M | ||
| Q4 24 | $-48.8M | $2.2M | ||
| Q3 24 | $-42.2M | $764.0K | ||
| Q2 24 | $-39.7M | $5.4M | ||
| Q1 24 | $-42.0M | $12.8M |
自由现金流NRIXRVSB
| Q4 25 | $-73.0M | $-736.0K | ||
| Q3 25 | $-60.1M | $16.4M | ||
| Q2 25 | $-65.8M | $-773.0K | ||
| Q1 25 | $-64.6M | $5.6M | ||
| Q4 24 | $-50.9M | $1.9M | ||
| Q3 24 | $-44.5M | $-1.4M | ||
| Q2 24 | $-41.6M | $5.3M | ||
| Q1 24 | $-44.8M | $7.1M |
自由现金流率NRIXRVSB
| Q4 25 | -537.4% | -5.2% | ||
| Q3 25 | -761.3% | 120.1% | ||
| Q2 25 | -149.4% | -5.8% | ||
| Q1 25 | -349.9% | 43.1% | ||
| Q4 24 | -382.8% | 15.0% | ||
| Q3 24 | -353.7% | -11.3% | ||
| Q2 24 | -344.4% | 43.7% | ||
| Q1 24 | -270.3% | 79.0% |
资本支出强度NRIXRVSB
| Q4 25 | 37.8% | 1.6% | ||
| Q3 25 | 34.3% | 2.9% | ||
| Q2 25 | 6.1% | 0.6% | ||
| Q1 25 | 18.9% | 21.0% | ||
| Q4 24 | 15.8% | 2.4% | ||
| Q3 24 | 18.6% | 17.3% | ||
| Q2 24 | 16.0% | 0.9% | ||
| Q1 24 | 17.4% | 62.0% |
现金转化率NRIXRVSB
| Q4 25 | — | -0.37× | ||
| Q3 25 | — | 15.25× | ||
| Q2 25 | — | -0.57× | ||
| Q1 25 | — | 7.20× | ||
| Q4 24 | — | 1.79× | ||
| Q3 24 | — | 0.49× | ||
| Q2 24 | — | 5.63× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NRIX
| Pfizer | $11.9M | 88% |
| Gilead Agreement | $1.7M | 13% |
RVSB
暂无分部数据
